218 related articles for article (PubMed ID: 37544974)
21. 3D-QSAR and scaffold hopping based designing of benzo[d]ox-azol-2(3H)-one and 2-oxazolo[4,5-b]pyridin-2(3H)-one derivatives as selective aldehyde dehydrogenase 1A1 inhibitors: Synthesis and biological evaluation.
Verma H; Narendra G; Raju B; Kumar M; Jain SK; Tung GK; Singh PK; Silakari O
Arch Pharm (Weinheim); 2022 Sep; 355(9):e2200108. PubMed ID: 35618489
[TBL] [Abstract][Full Text] [Related]
22. 3D-QSAR and Molecular Docking Studies on Oxadiazole Substituted Benzimidazole Derivatives: Validation of Experimental Inhibitory Potencies Towards COX-2.
Asati V; Ghode P; Bajaj S; Jain SK; Bharti SK
Curr Comput Aided Drug Des; 2019; 15(4):277-293. PubMed ID: 30280671
[TBL] [Abstract][Full Text] [Related]
23. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
[TBL] [Abstract][Full Text] [Related]
24. Pharmacophore-guided fragment-based design of novel mammalian target of rapamycin inhibitors: extra precision docking, fingerprint-based 2D and atom-based 3D-QSAR modelling.
Kumar A; Rai S; Rathi E; Agarwal P; Kini SG
J Biomol Struct Dyn; 2021 Mar; 39(4):1155-1173. PubMed ID: 32037974
[TBL] [Abstract][Full Text] [Related]
25. Anti-tubercular Modelling via QSAR Approach, In Silico Design and Virtual Docking Screening of Designed Hypothetical Inhibitors Against DNA gyrase Protein.
Adeniji SE
Curr Comput Aided Drug Des; 2021; 17(6):739-758. PubMed ID: 32586260
[TBL] [Abstract][Full Text] [Related]
26. A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors.
Tripuraneni NS; Azam MA
J Biomol Struct Dyn; 2016 Nov; 34(11):2481-92. PubMed ID: 26587754
[TBL] [Abstract][Full Text] [Related]
27. In-silico designing and characterization of binding modes of two novel inhibitors for CB1 receptor against obesity by classical 3D-QSAR approach.
Khan N; Halim SA; Khan W; Zafar SK; Ul-Haq Z
J Mol Graph Model; 2019 Jun; 89():199-214. PubMed ID: 30908997
[TBL] [Abstract][Full Text] [Related]
28. Searching for Potential Novel BCR-ABL Tyrosine Kinase Inhibitors Through G-QSAR and Docking Studies of Some Novel 2-Phenazinamine Derivatives.
Kale M; Sonwane G; Choudhari Y
Curr Comput Aided Drug Des; 2020; 16(5):501-510. PubMed ID: 30345925
[TBL] [Abstract][Full Text] [Related]
29. Molecular docking, QSAR and ADMET based mining of natural compounds against prime targets of HIV.
Vora J; Patel S; Sinha S; Sharma S; Srivastava A; Chhabria M; Shrivastava N
J Biomol Struct Dyn; 2019 Jan; 37(1):131-146. PubMed ID: 29268664
[TBL] [Abstract][Full Text] [Related]
30. 2D- and 3D-QSAR modelling, molecular docking and
Shukla A; Tyagi R; Meena S; Datta D; Srivastava SK; Khan F
J Biomol Struct Dyn; 2020 Jan; 38(1):168-185. PubMed ID: 30686140
[TBL] [Abstract][Full Text] [Related]
31.
Akabli T; Toufik H; Lamchouri F
J Biomol Struct Dyn; 2022 Jun; 40(9):3965-3978. PubMed ID: 33252029
[TBL] [Abstract][Full Text] [Related]
32. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
33. Multi-combined 3D-QSAR, docking molecular and ADMET prediction of 5-azaindazole derivatives as LRRK2 tyrosine kinase inhibitors.
Khamouli S; Belaidi S; Ouassaf M; Lanez T; Belaaouad S; Chtita S
J Biomol Struct Dyn; 2022 Feb; 40(3):1285-1298. PubMed ID: 32964807
[TBL] [Abstract][Full Text] [Related]
34. Reconnoitering imidazopyridazines as anticancer agents based on virtual modelling approach: quantitative structure activity relationship, molecular docking and molecular dynamics.
Mangala K; Vinayak W; Aasiya C; Chandrakant B; Amol M; Kumar D; Kulkarni R
J Biomol Struct Dyn; 2024 Mar; 42(5):2392-2409. PubMed ID: 37160699
[TBL] [Abstract][Full Text] [Related]
35. Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure.
Mahmoudi A; Butler AE; Banach M; Jamialahmadi T; Sahebkar A
Curr Probl Cardiol; 2023 Jun; 48(6):101660. PubMed ID: 36841313
[TBL] [Abstract][Full Text] [Related]
36. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
[TBL] [Abstract][Full Text] [Related]
37. In silico studies on potential MCF-7 inhibitors: a combination of pharmacophore and 3D-QSAR modeling, virtual screening, molecular docking, and pharmacokinetic analysis.
Badhani B; Kakkar R
J Biomol Struct Dyn; 2017 Jul; 35(9):1950-1967. PubMed ID: 27401212
[TBL] [Abstract][Full Text] [Related]
38. Molecular modelling of quinoline derivatives as telomerase inhibitors through 3D-QSAR, molecular dynamics simulation, and molecular docking techniques.
Vishwakarma K; Bhatt H
J Mol Model; 2021 Jan; 27(2):30. PubMed ID: 33415518
[TBL] [Abstract][Full Text] [Related]
39. Design of potential anti-tumor PARP-1 inhibitors by QSAR and molecular modeling studies.
Abbasi-Radmoghaddam Z; Riahi S; Gharaghani S; Mohammadi-Khanaposhtanai M
Mol Divers; 2021 Feb; 25(1):263-277. PubMed ID: 32140890
[TBL] [Abstract][Full Text] [Related]
40. An
Malkaje S; Srinivasa MG; Deshpande N S; Navada S; Revanasiddappa Bc
Curr Drug Res Rev; 2023; 15(1):88-100. PubMed ID: 36017854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
